The editor-in-chief of the New England Journal of Medicine accused three of the largest drug companies of ‘making a mockery‘ of efforts to create transparency in clinical trials, adding that could lead some important medical publications to avoid publishing their studies.
With a closely divided House poised to vote today on whether to expand federal funding of human embryonic stem cell research, opponents are offering fence-sitters what they say is an embryo-friendly alternative: a bill that would foster the use of stem cells from umbilical cords discarded after birth.
The U.S. government is dangling a big carrot — and some wheat and corn — to encourage manufacturers to make more products from biobased materials.
How does Genentech do it? The biotech company focuses on science — not marketing, acquisitions, or patents
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments